Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin | Zendy

Dipen Patel | Zendy; Jennifer Stephens | Zendy; Xin Gao | Zendy; Verheggen | Zendy; Ahmed Shelbaya | Zendy; Seema Haider | Zendy

Open Access

Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin

Author(s) -

Dipen Patel,

Jennifer Stephens,

Xin Gao,

Verheggen,

Ahmed Shelbaya,

Seema Haider

Publication year - 2013

Publication title -

clinicoeconomics and outcomes research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.591

H-Index - 27

ISSN - 1178-6981

DOI - 10.2147/ceor.s46991

Subject(s) - daptomycin , linezolid , medicine , vancomycin , antibiotics , intensive care medicine , pharmacy , emergency medicine , staphylococcus aureus , microbiology and biotechnology , family medicine , biology , bacteria , genetics

Previous economic analyses evaluating treatment of methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft-tissue infections (cSSTI) failed to include all direct treatment costs such as outpatient parenteral antibiotic therapy (OPAT). Our objective was to develop an economic model from a US payer perspective that includes all direct inpatient and outpatient costs incurred by patients with MRSA cSSTI receiving linezolid, vancomycin, or daptomycin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research